ECM Weekly (7 Sep 2019) - China Merchants Comm REIT, Immunotech Bio, Bank of Guizhou, XD, Huize
Aequitas Research puts out a weekly update on the deals that have been covered by Smartkarma Insight Providers recently, along with updates for...
524 Views
Shanghai Henlius Biotech IPO: Cash Breakeven Analysis
Shanghai Henlius Biotech (1566213D HK) is a biopharmaceutical company and a non-wholly owned subsidiary of Shanghai Fosun Pharmaceutical (Group)...
415 Views
Shanghai Henlius (复宏汉霖) IPO: Thoughts on Valuation
Shanghai Henlius, a subsidiary of Fosun Pharma, is seeking to list in Hong Kong. In our previous insights covering Shanghai Henlius, we have...
564 Views
Shanghai Henlius Biotech IPO Initiation: Going Large
Shanghai Henlius Biotech (1566213D HK) is a biopharmaceutical company and a non-wholly owned subsidiary of Shanghai Fosun Pharmaceutical (Group)...
646 Views
Shanghai Henlius (复宏汉霖) IPO: What's New in the Re-Filed Prospectus?
Shanghai Henlius, a subsidiary of Fosun Pharma, is seeking to list in Hong Kong. Shortly after its previous application lapsed, the company refiled...
688 Views